A recent Phase 3 CROWN trial has demonstrated the long-term effectiveness of LORBRENA in treating ALK-positive advanced non-small cell lung cancersmall cell lung cancerlung cancer (NSCLC). After five years of follow-up, patients treated with LORBRENA experienced a remarkable 81% reduction in disease progression or death compared to those receiving XALKORI.
Significantly, 60% of LORBRENA recipients remained alive without disease progression after five years, while only 8% of XALKORI achieved this milestone. These findings highlight LORBRENA’s potential as a standard treatment for ALK-positive advanced NSCLC.
LORBRENA’s efficacy in targeting tumor mutations and penetrating the blood-brain barrier is a breakthrough. Compared to XALKORI, it has significantly reduced the risk of intracranial disease progression by 94%. Among patients without brain metastases at the start of treatment, only a small number developed brain metastases within the first 16 months of LORBRENA use, compared to a higher incidence in the XALKORI group.
The improved outcomes with LORBRENA represent a significant advancement in lung cancer treatment. It offers patients with ALK-positive advanced NSCLC a better chance of long-term survival and reduced disease progression, including in the brain.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
